October 16, 2006 -- Amgen received an approvable letter for Aranesp on a less-rigorous dosing schedule; Pfizer and Eisai received approval of an extension for Alzheimer’s drug Aricept; Omrix announced positive results from a Phase III trial of its human thrombin product; Nabi said PhosLo, its phosphate-lowering drug, met its trial endpoint; Pain Therapeutics detailed the mechanism behind ultra-low-dose (ULD) opioid antagonists; Human Genome Sciences reported Albuferon outperformed pegylated interferon; Valortim, an anthrax therapy from Medarex, passed its Phase I tests; Serono in-licensed a Parkinson’s/ Alzheimer’s disease drug; and Tercica shareholders approved a collaboration with Ipsen. The Centient Biotech 200™ rose 16 points to 3947, a rise of .42%. More details...
